UBS Group’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.7M | Buy |
4,209,052
+2,269,643
| +117% | +$8.17M | ﹤0.01% | 2923 |
|
|
2025
Q4 | $6.63M | Sell |
1,939,409
-549,791
| -22% | -$2.45M | ﹤0.01% | 3735 |
|
|
2025
Q3 | $12.5M | Sell |
2,489,200
-958,725
| -28% | -$4.23M | ﹤0.01% | 3049 |
|
|
2025
Q2 | $11.8M | Sell |
3,447,925
-1,634,258
| -32% | -$4.07M | ﹤0.01% | 2911 |
|
|
2025
Q1 | $11.3M | Buy |
5,082,183
+3,106,835
| +157% | +$8.91M | ﹤0.01% | 2899 |
|
|
2024
Q4 | $5.79M | Buy |
1,975,348
+1,953,603
| +8,984% | +$5.44M | ﹤0.01% | 3668 |
|
|
2024
Q3 | $56.5K | Sell |
21,745
-73,246
| -77% | -$203K | ﹤0.01% | 6732 |
|
|
2024
Q2 | $281K | Sell |
94,991
-6,984
| -7% | -$26.4K | ﹤0.01% | 5427 |
|
|
2024
Q1 | $462K | Buy |
101,975
+99,475
| +3,979% | +$508K | ﹤0.01% | 5263 |
|
|
2023
Q4 | $14.3K | Buy |
+2,500
| New | +$11.6K | ﹤0.01% | 7285 |
|
|
2023
Q3 | – | Sell |
-13,366
| Closed | -$86.3K | – | 9400 |
|
|
2023
Q2 | $86.3K | Sell |
13,366
-53,532
| -80% | -$365K | ﹤0.01% | 6132 |
|
|
2023
Q1 | $504K | Buy |
66,898
+22,652
| +51% | +$206K | ﹤0.01% | 4681 |
|
|
2022
Q4 | $448K | Sell |
44,246
-50,592
| -53% | -$584K | ﹤0.01% | 4802 |
|
|
2022
Q3 | $938K | Buy |
94,838
+53,483
| +129% | +$587K | ﹤0.01% | 3801 |
|
|
2022
Q2 | $440K | Sell |
41,355
-21,070
| -34% | -$178K | ﹤0.01% | 4350 |
|
|
2022
Q1 | $609K | Sell |
62,425
-16,766
| -21% | -$159K | ﹤0.01% | 4553 |
|
|
2021
Q4 | $1.13M | Buy |
79,191
+15,784
| +25% | +$240K | ﹤0.01% | 4273 |
|
|
2021
Q3 | $1.27M | Buy |
63,407
+22,389
| +55% | +$396K | ﹤0.01% | 3984 |
|
|
2021
Q2 | $902K | Buy |
41,018
+37,949
| +1,237% | +$1.05M | ﹤0.01% | 4263 |
|
|
2021
Q1 | $104K | Buy |
3,069
+3,061
| +38,263% | +$122K | ﹤0.01% | 5930 |
|
|
2020
Q4 | $0 | Buy |
+8
| New | +$366 | ﹤0.01% | 8342 |
|
Other funds holding ABCL
BBA
TWC
ACH
DCM
